Companies
Mesoblast
the FDA accepted its Biologics License Application for Ryoncil (remestemcel-L) in children with steroid-refractory acute graft-versus-host disease, the lead allogeneic-MSC regulatory asset; remestemcel-L is the most-studied MSC in inflammatory disease.
- Country
- United States
- Ticker
- MESO
Commercial
MSC (remestemcel-L / Ryoncil)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Founded | 2004 | thecompanycheck.com |
| Funding | 16 rounds completed, latest $159.98M Post-IPO | thecompanycheck.com |
| Headcount | 81 employees (as of June 30, 2025) | thecompanycheck.com |
| Regulatory approval | FDA approval of Ryoncil (remestemcel-L-rknd) for pediatric SR-aGVHD on December 18, 2024 | fda.gov · isctglobal.org |
| Revenue | US$115M Ryoncil net revenue for the first full year post-FDA approval (ended June 30, 2026) | sec.gov |
Independent sources: fda.gov · isctglobal.org · sec.gov · thecompanycheck.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Stem cell therapy for autoimmune disease | therapeutics-platforms | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.